生物活性：(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor[1].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
(Rac)-Ruxolitinib-d9 相关抗体:
Phospho-JAK2 (Tyr1007/1008) Antibody
JAK1 Antibody (YA722)
JAK1 Antibody
JAK2 Antibody (YA721)
Phospho-JAK2 (Tyr1007+Tyr1008) Antibody
JAK2 Antibody (YA330)
Phospho-JNK (Thr183) Antibody
JAK3 Antibody (YA2466)
分子量：315.42
Formula：C17H9D9N6
CAS 号：2469553-67-9
非标记 CAS：941688-05-7
中文名称：芦可替尼杂质10-d9
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (536 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Yaoyu CHEN, et al. Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor. Patent WO2021102258A1